Transcription factors in chimeric antigen receptor T-cell development

Area of Science:

• Immunology
• Oncology
• Molecular Biology
• Gene Therapy

Background:

• Chimeric antigen receptor (CAR) T-cell therapy shows promise for lymphoma but is less effective against solid tumors.
• Limitations in solid tumor treatment necessitate combination strategies to enhance CAR T-cell efficacy.
• Transcription factors (TFs) regulate gene expression and can modulate CAR T-cell function.

Purpose of the Study:

• To review the application of transcription factors (TFs) in CAR T-cell therapy for solid tumors.
• To explore how targeting TFs can enhance synergistic therapeutic effects and anti-tumor responses.
• To improve CAR T-cell cytotoxicity, survival, and reduce exhaustion in solid tumor treatment.

Main Methods:

• Review of current research on transcription factor manipulation in CAR T-cell therapy.
• Analysis of TF mechanisms in regulating CAR T-cell phenotype and transcriptional landscape.
• Evaluation of strategies to enhance CAR T-cell effector functions via TF targeting.

Main Results:

• Transcription factors can be targeted to modify CAR T-cells, improving their anti-tumor activity.
• TF modulation enhances CAR T-cell effector functions, including increased cytotoxicity and survival.
• Targeting TFs shows potential to overcome CAR T-cell exhaustion in the tumor microenvironment.

Conclusions:

• Transcription factor-based strategies offer a promising approach to enhance CAR T-cell therapy for solid tumors.
• Modulating TFs can improve CAR T-cell persistence, function, and overall anti-tumor efficacy.
• Further research into TF applications could lead to more effective cancer immunotherapies.